These toxins are natural products and produced by bacteria, therefore pharmaceutical batch-to-batch variations in concentration and activity occur. However, since the toxins e.g. Botox® are approved by the national regulatory authorities as pharmaceuticals, the safety for the patients has to be guaranteed by batch testing of the final product. Currently, the potency of biologically-active BoNT is monitored by intoxicating mice in so called mouse biosassay (MBA) that was introduced in the 1920s. In this assay, different dilutions of preparations containing BoNT are injected into mice and symptoms of paralysis are observed for several hours up to days. Due to the enormous demand for pharmaceutical products containing BoNT, it is estimated that in the USA and Europe, annually more than 600,000 mice are sacrificed for these batch tests. This large amount of animals and suffering causes considerable ethical concerns. Therefore, there is a high demand for the replacement of the MBA. In response to this high demand, a novel in vitro assay as an alternative to the widely used in vivo MBA has been developed by Stephen Jenkinson a PhD student in the lab of Prof. Dr. med. Stephen Leib at the Institute for Infectious Diseases in collaboration with the Department of Physiology , both at the University of Bern and with the Spiez Laboratory, Swiss Federal Office for Civil Protection.
Growing new neurons
In the sudy the researchers demonstrated that neurons differentiated in vitro from mouse embryonic stem cells cultured on multi-electrode arrays (MEAs) can serve as a physiologically relevant cell-based method for detecting BoNT/A holotoxin and complex. The neuronal cultures formed functional networks composed of a heterogeneous mixture of excitatory and inhibitory neurons and upon treatment for 24 hours with ~ 1 pM BoNT/A holotoxin or Botox® a complete silencing of synaptic transmission was observed. «Detection and quantification of BoNTs in pharmaceutical preparations is extremely challenging due to a multistep mechanism of cellular intoxication and the high potency of the toxins», says Stephen Jenkinson, first author of the study. To date, neuronal cell-based methods are the only in vitro alternative to the MBA and several assays have been developed using primary or embryonic stem cell derived neurons that show similar or even greater sensitivity than the MBA. However, most of these assays rely on destructive homogenization of tissue to allow BoNT quantification and assessment thus requiring additional methods and further hands-on time to yield a result. «In addition, these methods do not allow a continuous monitoring of neuronal activity upon treatment with BoNTs», adds Stephen Leib.
The main advantage of this assay is the usage of stem cell derived neurons, thus making the usage of animals obsolete. Further, MEA recording techniques allow for a continuous non-invasive monitoring of neuronal activity and this approach can be easily up-scaled to meet the requirements for a prospective high-throughput screening of neuroactive compounds. «In addition, the usage of commercially available MEA systems do not require highly trained staff», says Jenkinson. Though the presented assay holds a high sensitivity down to 1 pM of BoNT/A, further research has to be conducted in increasing the overall sensitivity. However, Stephen Jenkinson and Stephen Leib believe that the novel bioassay holds great potential to reduce animal use for BoNT detection and activity determination in pharmaceuticals. In addition, the assay can be expanded for the drug-screening of possible neuroactive compounds with an emphasis on synaptic activity. The study has now been published in Frontiers in Pharmacology.